| Literature DB >> 28706394 |
Biswajit Dey1, Mangesh Chikhale1, Prita Pradhan1, Adarsh Barwad1, Bhawana Ashok Badhe1.
Abstract
Osteochondroma is the most common benign bone tumor. Approximately 15% of osteochondromas occur as multiple lesions. Multiple osteochondromatosis has a higher risk of developing chondrosarcomas, which are of low grade with good prognosis. About 10% of all chondrosarcomas may undergo dedifferentiated change, which has a poorer prognosis. Dedifferentiated peripheral chondrosarcoma developing within an osteochondroma is extremely rare. Dedifferentiation usually occurs in the form of osteosarcoma, malignant fibrous histiocytoma, fibrosarcoma, or rhabdomyosarcoma. We report a case of proximal epithelioid sarcomatous dedifferentiation in secondary chondrosarcoma in a 39-year-old male with multiple osteochondromatosis in bilateral arm. To the best of our knowledge, epithelioid sarcomatous dedifferentiation has not been described in the literature.Entities:
Keywords: Osteochondroma; sarcoma; secondary
Year: 2017 PMID: 28706394 PMCID: PMC5496302 DOI: 10.4103/0974-2727.208253
Source DB: PubMed Journal: J Lab Physicians ISSN: 0974-2727
Figure 1(a) Contrast-enhanced computed tomography showed a heterogeneously enhancing mass arising from metaphyseal-diaphyseal region of proximal shaft of right humerus. (b) Right-sided forequarter amputation gross specimen showed a mass measuring 28 cm × 27 cm × 20 cm in the right shoulder region
Figure 2(a) Histopathology showed low-grade chondrosarcoma permeating into marrow spaces (H and E, ×100). (b) High-grade sarcomatous areas composed of tumor cells arranged in sheets and nodules with epithelioid differentiation (H and E, ×100). (c) The tumor cells had round to oval nuclei, coarse chromatin, conspicuous nucleoli, and moderate to abundant cytoplasm (H and E, ×400). (d) Pancytokeratin positivity in the tumor cells in the sarcomatous area (immunohistochemistry, ×400). (e) Vimentin positivity in the tumor cells in the sarcomatous area (immunohistochemistry, ×400). (f) Loss of integrase interactor-1 in the sarcomatous area (immunohistochemistry, ×400)